Since becoming only the second Alzheimer’s-modifying drug to gain American Federal Drug Administration approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87 million USD in the last quarter of 2024.
Since becoming only the second Alzheimer’s-modifying drug to gain American Federal Drug Administration approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87 million USD in the last quarter of 2024.
Leave A Comment